CA
NZ
UK
AU
IND
US
Q32 Bio (NASDAQ: QTTB) announced top‑line data from the second segment of its SIGNAL‑AA Phase 2a study, evaluating the experimental therapy bempikibart in adults with severe alopecia areata.
Sunshine Biopharma Inc. Disclosed a definitive settlement on July 8, 2026 that resolves a dispute with its former subsidiary head, Malek Chamoun. The agreement clears a legal cloud that has lingered over the biotech firm’s recent operational initiatives.
Traws Pharma, Inc. (NASDAQ: TRAW) has finalized an at-the-market (ATM) stock sale agreement, providing the company with a strategic tool to raise capital as needed. This method allows Traws Pharma to issue shares gradually, aligning with the financial strategies commonly adopted by biotech and …
Aligos Therapeutics Inc. (NASDAQ: ALGS) announced the completion of enrollment in its Phase 2 B-SUPREME study for pevifoscorvir sodium, a potential treatment for chronic hepatitis B virus (HBV) infection. The news triggered a 3% decline in pre-market trading, reflecting investor caution as the biotech …
Silo Pharma, Inc. (NASDAQ: SILO) reported the successful closing of a private placement on July 10, 2026, generating gross proceeds in the vicinity of $3.5 million after the deduction of applicable fees. The capital raise was structured to combine equity issuance with a layered …
Tenon Medical moved quickly after receiving a Nasdaq compliance notice earlier this year, securing fresh capital to stave off potential delisting. The medical‑device firm disclosed that it sold $4.2 million of common stock and warrants in a public offering, aiming to meet the exchange’s …
Voyager Therapeutics (NASDAQ: VYGR) has shared new preclinical findings for VY1706, its experimental gene therapy targeting tau protein in Alzheimer’s disease. The results, disclosed at a scientific meeting, suggest the therapy may address a fundamental mechanism underlying disease progression.
Oncolytics Biotech Inc (TSX: ONCY) issued a regulatory notice outlining recent progress within its REO 033 investigation. The notice highlights forthcoming dialogue with U.S. Health regulators and offers investors a concise overview of the program’s status.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) shared the outcomes of its annual shareholders’ meeting, which took place on July 7, 2026. The gathering addressed several key governance and capital‑structure items, reflecting the company’s ongoing efforts to support its growing pipeline in oncology therapeutics.
Dare Bioscience has formally submitted a corporate presentation to regulators, marking a step in its investor communications strategy. The document, dated July 13, 2026.S. Securities and Exchange Commission. This move precedes planned discussions with market participants.
Please wait processing your request...